Evaluation of Serum Ages Levels in Patients With Endometriosis

Completed

• Conditions: Endometriosis

• Registration Number: NCT04886024
• Lead Sponsor: Kanuni Sultan Suleyman Training and Research Hospital

Brief Summary

Serum AGES (Advanced Glycation End Products) levels of endometriosis patients are compared with a group of healthy volunteers of the same age.

Detailed Description

Serum AGES (Advanced Glycation End Products) levels are compared with 45 endometriosis patients and 45 healthy volunteers of the same age. The energy metabolism of the endometriosis group and its possible relationship with the endometriosis stage will be compared since AGES (Advanced Glycation End Products) gives information about the energy metabolism of the people.

Study Timeline

• Study Start: 2020-12-05
• Study First Submitted: 2021-05-09
• Study First Submitted QC: 2021-05-09
• Study First Posted: 2021-05-13
• Primary Completion: 2021-07-20
• Study Completion: 2021-07-30
• Status Verified: 2021-08
• Last Update Submitted: 2021-08-30
• Last Update Posted: 2021-08-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 90

Inclusion Criteria

• diagnosed with endometriosis (Surgery or ultrasound)
• Women without endometriosis

Exclusion Criteria

• Women without endometriosis women who are only suspected endometriosis

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum Advanced Glycation End Products (AGEs) levels in women with endometriosis	8 months	Serum Serum Advanced Glycation End Products (AGEs) levels involved in inflammation and energy metabolism are compared between endometriosis and healthy control group

Secondary Outcome Measures

Name	Time	Method
Comparison of the relationship between serum Serum Advanced Glycation End Products (AGEs) level and endometriosis stage	8 months	By comparing the relation of serum Advanced Glycation End Products (AGEs) level with the stage of endometriosis, its relation with serum level in patients with advanced and early stage endometriosis will be examined. The possible effect of Advanced Glycation End Products (AGEs) on disease pathogenesis will be examined.

Trial Locations

Locations (1)

Pinar Yalcin Bahat; 🇹🇷 Istanbul, İ̇stanbul, Turkey